Assignee
HARBOUR BIOMED SHANGHAI CO LTD
CN·4 granted patents·19 pending applications·1 citations·filing 2018–2025
Top patents by PatentIndex Score
23 records- 0182US12428479B2CLDN18.2-targeting antibody, bispecific antibody and use thereofHARBOUR BIOMED SHANGHAI CO LTD·Filed 2022·Granted Sep 30, 2025·1 cites·17 claims
- 0271US2026062493A1Antibody Targeting BCMA, Bispecific Antibody, And Use ThereofHARBOUR BIOMED SHANGHAI CO LTD·Filed 2025·Application pending·0 cites
- 0362US2025340631A1Cldn18.2-targeting antibody, bispecific antibody and use thereofHARBOUR BIOMED SHANGHAI CO LTD·Filed 2025·Application pending·0 cites
- 0458US2025326843A1Bispecific antibody combination and use thereofHARBOUR BIOMED SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 0558US2025313626A1Anti-cd200r1 antibodiesHARBOUR BIOMED SHANGHAI CO LTD·Filed 2023·Application pending·0 cites
- 0656US12240905B2Antibodies binding CTLA-4 and uses thereofHARBOUR BIOMED SHANGHAI CO LTD·Filed 2021·Granted Mar 4, 2025·0 cites·20 claims
- 0756US2025215100A1Antigen binding protein targeting cd40, and preparation therefor and use thereofHARBOUR BIOMED SHANGHAI CO LTD·Filed 2023·Application pending·0 cites
- 0856US2025136694A1Anti-b7-h4 antibody, and preparation method therefor and use thereofHARBOUR BIOMED SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 0956US2025136696A1Anti-b7-h7 antibody or antigen-binding fragment thereof, and preparation method therefor and use thereofHARBOUR BIOMED SHANGHAI CO LTD·Filed 2023·Application pending·0 cites
- 1053US2024050583A1Protein-drug conjugate and site-specific conjugating methodHARBOUR BIOMED SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 1152US2023287143A1Binding protein in fab-hcab structureHARBOUR BIOMED SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 1252US2025215089A1Antigen-binding protein targeting pd-l1 and cd40, preparation therefor, and use thereofHARBOUR BIOMED SHANGHAI CO LTD·Filed 2023·Application pending·0 cites
- 1352US2023303698A1Multispecific binding protein of immune cell engager, preparation therefor and application thereofHARBOUR BIOMED SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 1451US2024010721A1Ror1-targeting antibody or antigen-binding fragment thereof, preparation method therefor, and application thereofHARBOUR BIOMED SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 1550US2024269276A1Specific binding protein targeting pd-l1 and cd73HARBOUR BIOMED SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 1650US2023295324A1Ox40-targeted antibody, and preparation method therefor and application thereofHARBOUR BIOMED SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 1749US2023235090A1Bispecific antibody and use thereofHARBOUR BIOMED SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 1849US2023322953A1Binding protein having h2l2 and hcab structuresHARBOUR BIOMED SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 1948US11098122B2Antibodies binding CTLA-4 and uses thereofHARBOUR BIOMED SHANGHAI CO LTD·Filed 2018·Granted Aug 24, 2021·0 cites·17 claims
- 2047US2024270847A1Antibody binding ctla-4 and use thereofHARBOUR BIOMED SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 2146US12545732B2PD-1 antigen-binding protein and use thereofHARBOUR BIOMED SHANGHAI CO LTD·Filed 2021·Granted Feb 10, 2026·0 cites·24 claims
- 2246US2022411513A1Anti-pd-l1 antigen binding protein and application thereofHARBOUR BIOMED SHANGHAI CO LTD·Filed 2020·Application pending·0 cites
- 2343US2023357425A1Anti-cd73 antibody and application thereofHARBOUR BIOMED SHANGHAI CO LTD·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when HARBOUR BIOMED SHANGHAI CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →